Dian Diagnostics: It is expected that AI business revenue will maintain a compound annual growth rate far exceeding 100% over the next three years

Zhitong
2025.06.09 02:56

Dian Diagnostics stated in an institutional research that the company's AI-related business revenue in 2024 is expected to be approximately 20 million yuan, mainly derived from the commercialization of AI pathology and other auxiliary diagnostic products and specialized disease database products. The company invests tens of millions of yuan annually in the AI field, focusing primarily on three core areas: data platforms, pathology AI, and health management. According to the three-year strategic plan, the AI business covers four directions: AI-driven clinical decision support, health management, AI + CRO services for pharmaceutical companies, and data foundation and regional "smart inspection linkage" business. It is expected that in the next three years, AI business revenue will maintain a compound annual growth rate far exceeding 100%

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer